The popularity of Sildenafil initially drove a surge for major pharmaceutical companies, but recent changes present a complicated outlook for those considering a stake. Off-patent versions are eroding revenue, and https://haseebpxyh156388.blogmazing.com/40015160/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet